Aspire Biopharma Holdings, Inc.
No enriched coverage for $ASBP in the last 7 days.
No SEC Form 4 filings for $ASBP in the last 30 days.
Aspire Biopharma Holdings (ASBP) will implement a 1-for-30 reverse stock split on May 11, 2026. This action will consolidate shares, reduce the total share count, and assign a new CUSIP number while retaining the existing ticker symbol. The company, operating in the biopharmaceutical sector, aims to manage its market position through this capital markets action.
Aspire Biopharma Holdings, Inc. announced its Letter of Intent to acquire Dura Driver Control Systems (DCS), a leading global automotive supplier. The acquisition, valued at $30 million in cash, is expected to transform Aspire into a diversified, high-revenue enterprise, leveraging DCS's robust financial performance of over $200 million in revenue and $20 million in Adjusted EBITDA for FY2025. DCS specializes in automotive driver control systems with a strong patent portfolio and global manufacturing presence.
Aspire Biopharma (NASDAQ:ASBP), a biopharmaceutical company, has signed a Letter of Intent to acquire Dura Driver Control Systems (DCS), a global automotive supplier, for $30 million in cash. DCS reported over $200 million in revenue and $20 million in adjusted EBITDA for FY2025 (unaudited), marking a significant diversification for Aspire Biopharma from its biotech focus into the automotive industry. The acquisition is subject to due diligence and a U.S. GAAP audit, and if completed, will bolster DCS's management with experienced automotive leadership.
